ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
Want to see AKBLF full AI Analyst Report?
AKBLF Stock Chart & Stats
$33.60
-$2.05(-9.17%)
At close: 4:00 PM EST
$33.60
-$2.05(-9.17%)
Day’s Range― - ―
52-Week Range$25.30 - $42.20
Previous CloseN/A
Volume1.00
Average Volume (3M)33.00
Market Cap
$8.92B
Enterprise Value$41.49B
Total Cash (Recent Filing)$316.00M
Total Debt (Recent Filing)$990.00M
Price to Earnings (P/E)25.6
Beta0.54
Next Earnings
Aug 20, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.28
Shares Outstanding202,567,200
10 Day Avg. Volume100
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.65
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda26.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALK-abello News
AKBLF FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was $25.30 and its highest was $42.20 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $8.92B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Aug 20, 2026 which is in 91 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on May 04, 2026. The company reported $0.311 earnings per share for the quarter, beating the consensus estimate of $0.264 by $0.047.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B pays a Annually dividend of $0.25 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 0.23.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of $0.311 in its last earnings report, beating expectations of $0.264. Following the earnings report the stock price went up 7.001%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in AKBLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
AKBLF Company Deck
AKBLF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company delivered strong Q1 financial results (18% revenue growth, 22% EBIT growth, 32% EBIT margin), achieved a major tablet sales milestone (over DKK 1 billion in a quarter), upgraded full-year guidance, reported robust regional and anaphylaxis product growth, and announced a successful Phase II peanut trial and key neffy regulatory approvals. Notable challenges include higher capacity costs (+23%), international shipment phasing (notably Japan) causing a -17% tablet decline in some markets, partner-related lower-margin revenue expected to rise, neffy market-access hurdles (UK local formularies, U.S. access), potential German pricing/rebate risk, and planned increased R&D/commercial spending for upcoming phases. Overall, the positives materially outweigh the negatives given upgraded guidance, cash generation, and strategic clinical progress.View all AKBLF earnings summariesTechnical Analysis
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
Ownership Overview
― Insiders
3.64% Mutual Funds
― Other Institutional Investors
90.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---